2025
Use of AMD3100 for Bone Marrow Derived Mesenchymal Stem Cells Mobilization in the Treatment of Murine Asherman’s Syndrome
Flores V, Delis P, Mamillapalli R, Taylor H. Use of AMD3100 for Bone Marrow Derived Mesenchymal Stem Cells Mobilization in the Treatment of Murine Asherman’s Syndrome. F&S Science 2025 PMID: 40818715, DOI: 10.1016/j.xfss.2025.08.003.Peer-Reviewed Original ResearchAsherman's syndromePreterm ruptureAS inductionMurine modelProgenitor cellsMesenchymal stem cell mobilizationMice treated with AMD3100Preterm rupture of membranesAMD3100-treated miceRupture of membranesOptimal timingStem cell mobilizationBone marrow transplantationTreatment groupsLevels of CXCL12Source of progenitor cellsRecurrent pregnancy lossEndometrial progenitor cellsBMD-MSCsLikelihood of pregnancyHysteroscopic adhesiolysisPlacental abruptionUterine repairSevere ASMarrow transplantation
2024
THE USE OF AMD3100 FOR BONE MARROW DERIVED MESENCHYMAL STEM CELLS MOBILIZATION IN THE TREATMENT OF ASHERMAN’S SYNDROME
Flores V, Delis P, Mamillapalli R, Taylor H. THE USE OF AMD3100 FOR BONE MARROW DERIVED MESENCHYMAL STEM CELLS MOBILIZATION IN THE TREATMENT OF ASHERMAN’S SYNDROME. Fertility And Sterility 2024, 122: e36-e37. DOI: 10.1016/j.fertnstert.2024.07.168.Peer-Reviewed Original ResearchMesenchymal stem cell mobilizationTreatment of Asherman's syndromeStem cell mobilizationAsherman's syndromeCell mobilization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply